Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Boehringer Ingelheim
Medtronic
Express Scripts
McKesson

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,399,413


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,399,413
Title:Low frequency glatiramer acetate therapy
Abstract: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
Inventor(s): Klinger; Ety (Tel Aviv, IL)
Assignee: Yeda Research & Development Co., Ltd. (Rehovot, IL)
Application Number:12/806,684
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,399,413
Patent Claim Types:
see list of patent claims
Use; Composition;

Recent additions to Drugs Protected by US Patent 8,399,413

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE 020622 Dec 20, 1996 DISCN No   Start Trial   Start Trial U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE 020622 Feb 12, 2002 RX Yes   Start Trial   Start Trial U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE 020622 Jan 28, 2014 RX Yes   Start Trial   Start Trial U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,399,413

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 AP RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING MS BY ADMINISTERING COPAXONE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Boehringer Ingelheim
Mallinckrodt
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.